Clinical trials: Patient Derived Organoid
Recurrent High Grade Glioma
PTCs-based Precision Treatment Strategy on Recurrent High-grade Gliomas
This trial is an open-label, single-arm, phase 0/1 study of high-grade glioma that aims to evaluate the feasibility, preliminary efficacy and safety of the precision treatment strategy.
- Trial name
- NCT05473923
- Testing
- Receiving chemotherapeutic or targeted drugs recommended by molecular tumor board.
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Tiantan Hospital
Eye Abnormalities
Modeling Ocular Developmental Diseases From 3D Cultures of Optic Vesicle Organoids Derived From hiPSCs of Patients With Ocular Malformations
Ocular morphogenesis is a complex process starting as early as the 4th week of embryonic life, involving interactions between varioustissues of different origin and conserved genes.
- Trial name
- OrganoEye (NCT06408701)
- Testing
- Blood sampling
- Where
- 2 sites in France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Toulouse
Colorectal Cancer
The Culture of Advanced/Recurrent/Metastatic Colorectal Cancer Organoids and Drug Screening
The study aims to establish an organoids platform and apply them to screen drugs for advanced/recurrent/metastatic colorectal cancer patients.
- Trial name
- NCT05304741
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chongqing University Cancer Hospital
Glioblastoma, Glioma, Malignant
Grafts of GSCs Into Brain Organoids for Testing Anti-invasion Drugs
In patients operated for glioblastoma, glioma stem-like cell lines will be obtained from tumor tissue, and IPSCs from skin fibroblasts or PBMCs.
- Trial name
- 2253 (NCT05772741)
- Testing
- Biological sample collection
- Where
- Italy
- Volunteers
- 160 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Crohn's Diseases, Crohn's Disease
A Phase 1 Study of ATORM-C in Patients With Crohn's Disease
This Phase 1 study evaluates the safety and tolerability of ATORM-C in patients with Crohn's disease. ATORM-C is an investigational product consisting of autologous adult stem cell-derived intestinal organoids.
- Trial name
- NCT07822087
- Testing
- Autologous Adult Stem Cell-Derived Intestinal Organoid
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- ORGANOIDSCIENCES LTD.
Breast Cancer, Refractory Breast Carcinoma
Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer
This multicenter, open-label, randomized phase III trial is designed to study the efficacy and safety of organoid-guided personalized treatment （OGPT）versus treatment of physician's choice (TPC) in previously treated refractory…
- Trial name
- NCT06268652
- Testing
- Organoid-guided personalized treatment, Gemcitabine, Capecitabine
- Where
- China
- Volunteers
- 302 people
- Sponsor
- Sun Yat-sen University
Metastatic Colorectal Cancer
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
The purpose of the study is to investigate the effect and side effects of personalized cancer treatment in patients with metastatic colorectal cancer (bowel cancer).
- Trial name
- EVIDENT (NCT05725200)
- Testing
- Alectinib, Cetuximab, Crizotinib
- Where
- Norway
- Volunteers
- 40 people
- Sponsor
- Oslo University Hospital
Pancreas Cancer, Pancreas Neoplasm
Patient-derived Organoids Drug Screen in Pancreatic Cancer
Few chemotherapeutic options exist for pancreatic cancer. Moreover, objective criteria are lacking for deciding which regimen is more beneficial for patient presenting with metastases at diagnosis.
- Conditions
- Pancreas Cancer, Pancreas Neoplasm, Pancreas Adenocarcinoma, Pancreatic Cancer
- Trial name
- NCT05351983
- Testing
- Surgical biopsy of tumoral tissue for organoid generation
- Where
- Switzerland
- Volunteers
- 60 people
- Sponsor
- Prof. Dr. med. Dres. h.c. Jan Schmidt, MME
Lung Cancer
Organoid-guided Personalized Treatment of Pleural Effusion
The study is a single-arm, single-center clinical research that utilizes patient-derived tumor organoids to predict drug sensitivity, thereby assisting clinicians in formulating treatment plans to benefit lung cancer patients…
- Trial name
- NCT06959173
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Henan Cancer Hospital
Invasive Breast Cancer
Patient-Derived Breast Cancer Organoids for Therapeutic Extracellular Vesicle Isolation (PDO-Mercurial01)
The aim of this study is to establish organoid cultures, which are three-dimensional in vitro tumor models capable of supporting the long-term ex vivo growth of tumor cells derived from patients with breast carcinoma.
- Trial name
- PDO-Mercurial (NCT07421479)
- Testing
- Blood and tumor tissue collection
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Cholangiocarcinoma
Study on Consistency Evaluation for Drug Sensitivity of Patient-Derived Organoid Model From Cholangiocarcinoma Patients
This is a single-center, prospective, observational and exploratory clinical study. The object of this study is to evaluate the consistency and accuracy of patient-derived organoid model of cholangiocarcinoma to predict the…
- Trial name
- NCT05634694
- Testing
- No interventions.
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Ovarian Neoplasms
The Culture of Advanced or Recurrent Ovarian Cancer Organoids and Drug Screening
Most ovarian cancer will relapse after standard therapy. Patients with recurrent ovarian cancer are resistant to platinum. Due to the high heterogeneity between ovarian cancer, individual precise therapy is of great importance.
- Trial name
- NCT05290961
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chongqing University Cancer Hospital
Rectum Cancer
Patient-Derived Organoids for Rectal Cancer
The purpose of this study is to determine the feasibility of establishing patient-derived organoids from pre-treatment rectal adenocarcinoma biopsies.
- Trial name
- NCT04371198
- Testing
- Biopsy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Duke University
Unresectable Hepatocellular Carcinoma
A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma
This is a prospective, non-randomized, open-label, single-center phase II clinical trial. It aims to evaluate the efficacy and feasibility of using patient-derived tumor organoid drug sensitivity testing (DST) to guide…
- Trial name
- NCT07351513
- Testing
- Organoid Drug Sensitivity Testing-Guided Therapy
- Volunteers
- 94 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Pancreatic Cancer
Pharmacotyping of Pancreatic Patient-derived Organoids
EUS-FNB samples will be used for organoid cultures, which will be co-cultured with cancer associated fibroblasts derived from the surrounding stroma of the lesion.
- Trial name
- NCT05196334
- Testing
- No intervention
- Where
- Denmark
- Volunteers
- 88 people
- Sponsor
- Herlev Hospital
Explore the Consistency of Drug Sensitivity Between Primary Colorectal Cancer and Liver Metastases
Patient-derived Organoids Predicts the Clinical Efficiency of Colorectal Liver Metastasis
Accumulating evidence indicates that patient- derived organoids (PDOs) can predict drug responses in the clinic. Metastasis is the main cause of death in colorectal cancer patients, and the treatment of patients with liver…
- Trial name
- NCT05183425
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Changhai Hospital
Head and Neck Squamous Cell Carcinoma, Patient Derived Organoid
PDO Based Drug Sensitive Test in R/M HNSCC
To evaluate the consistency of drug efficacy between the clinical systemic treatment and drug sensitive test based on patient-derived organoid in R/M HNSCC patients, using a prospective and multicenter observational study to…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Patient Derived Organoid, Drug Sensitive Test in Vitro
- Trial name
- NCT06686342
- Testing
- No intervention, No Intervention: Observational Cohort
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Huashan Hospital
Metastatic Colorectal Cancer, BRAF V600E Mutation
Primary and Acquired Resistance to Targeted Treatment in BRAF V600E-mutated Metastatic Colorectal Cancer
This study prospectively investigates the molecular mechanisms of primary and acquired resistance to standard-of-care BRAF V600E-directed therapy in patients with metastatic colorectal cancer and aims to pre-clinically develop…
- Trial name
- PARTACER (NCT07617610)
- Testing
- Longitudinal translational sampling
- Where
- 13 sites in Switzerland
- Volunteers
- 30 people
- Sponsor
- Swiss Cancer Institute
Hepatocellular Carcinoma
Construction of a Recurrence Risk Prediction Model for Liver Resection Based on Drug Sensitivity of Patient-derived Hepatocellular Carcinoma Organoid
Liver cancer is the sixth most common malignant tumor worldwide and the third leading cause of cancer-related deaths. China is a high-risk area for liver cancer, accounting for approximately 55% of primary liver cancer worldwide.
- Trial name
- NCT06699524
- Testing
- in vitro （chemotherapy）, Adjuvant TACE（Adjuvant Transarterial Chemoembolization）
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Shen Feng
Glioblastoma
Patient-derived Glioma Stem Cell Organoids
Rationale: Glioblastoma (GM) is the most frequent incurable adult brain tumor with median survival of 15 months after diagnosis, despite extensive treatment with surgery, radiation therapy and chemotherapy.
- Trial name
- NCT04868396
- Testing
- Tumor biopsy
- Where
- 2 sites in Netherlands
- Volunteers
- 60 people
- Sponsor
- Maastricht Radiation Oncology